Joannnag的个人主页 - 老虎社区

Joannnag

暂无个人介绍

IP属地：未知

1关注

1粉丝

0主题

0勋章

2021-06-26

It takes time

抱歉，原内容已删除

2021-06-26

It takes time

抱歉，原内容已删除

2021-06-25

Oh no

抱歉，原内容已删除

2021-06-25

Wow

Eli Lilly Surges After Getting Breakthrough Therapy Designation From FDA, Analyst Raises PT and Sees Approval Chance at 90%, Biogen Plunges

2021-06-25

Nice!

抱歉，原内容已删除

2021-06-25

When ipo?

Chinese ride-hailing giant DiDi targets over $60 bln valuation in NYSE debut

2021-06-25

Good news!

抱歉，原内容已删除

2021-06-22

Great

抱歉，原内容已删除

2021-06-22

Hopefully soon!

抱歉，原内容已删除

2021-06-22

Really

5 Ultra-Popular Stocks Wall Street Views as Overvalued

2021-06-20

Really?

抱歉，原内容已删除

2021-06-20

Great

抱歉，原内容已删除

2021-06-20

Up

抱歉，原内容已删除

去老虎APP查看更多动态

{"i18n":{"language":"zh_CN"},"userPageInfo":{"id":"3575079452242155","uuid":"3575079452242155","gmtCreate":1611985883185,"gmtModify":1611985883185,"name":"Joannnag","pinyin":"joannnag","introduction":"","introductionEn":null,"signature":"","avatar":"https://static.laohu8.com/default-avatar.jpg","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":1,"headSize":1,"tweetSize":13,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖（非转发）","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-2","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"资深虎友","description":"加入老虎社区1000天","bigImgUrl":"https://static.tigerbbs.com/0063fb68ea29c9ae6858c58630e182d5","smallImgUrl":"https://static.tigerbbs.com/96c699a93be4214d4b49aea6a5a5d1a4","grayImgUrl":"https://static.tigerbbs.com/35b0e542a9ff77046ed69ef602bc105d","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.02.11","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":2,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":4,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":125453057,"gmtCreate":1624687778979,"gmtModify":1633949543908,"author":{"id":"3575079452242155","authorId":"3575079452242155","name":"Joannnag","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3575079452242155","authorIdStr":"3575079452242155"},"themes":[],"htmlText":"It takes time","listText":"It takes time","text":"It takes time","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/125453057","repostId":"1164137597","repostType":4,"isVote":1,"tweetType":1,"viewCount":515,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":125459754,"gmtCreate":1624687778978,"gmtModify":1633949544029,"author":{"id":"3575079452242155","authorId":"3575079452242155","name":"Joannnag","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3575079452242155","authorIdStr":"3575079452242155"},"themes":[],"htmlText":"It takes time","listText":"It takes time","text":"It takes time","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/125459754","repostId":"1164137597","repostType":4,"isVote":1,"tweetType":1,"viewCount":731,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":126417020,"gmtCreate":1624581560460,"gmtModify":1633951024257,"author":{"id":"3575079452242155","authorId":"3575079452242155","name":"Joannnag","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3575079452242155","authorIdStr":"3575079452242155"},"themes":[],"htmlText":"Oh no","listText":"Oh no","text":"Oh no","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/126417020","repostId":"1162964404","repostType":4,"isVote":1,"tweetType":1,"viewCount":572,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":126415165,"gmtCreate":1624581521157,"gmtModify":1633951025984,"author":{"id":"3575079452242155","authorId":"3575079452242155","name":"Joannnag","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3575079452242155","authorIdStr":"3575079452242155"},"themes":[],"htmlText":"Wow","listText":"Wow","text":"Wow","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/126415165","repostId":"2145042230","repostType":4,"repost":{"id":"2145042230","kind":"news","pubTimestamp":1624578900,"share":"https://ttm.financial/m/news/2145042230?lang=&edition=full","pubTime":"2021-06-25 07:55","market":"us","language":"en","title":"Eli Lilly Surges After Getting Breakthrough Therapy Designation From FDA, Analyst Raises PT and Sees Approval Chance at 90%, Biogen Plunges","url":"https://stock-news.laohu8.com/highlight/detail?id=2145042230","media":"StreetInsider","summary":"Shares of Eli Lilly and Company (NYSE: LLY) are up over 9% in today’s trading session after the comp","content":"<p>Shares of Eli Lilly and Company (NYSE: LLY) are up over 9% in today’s trading session after the company obtained the Breakthrough Therapy designation by the U.S. Food and Drug Administration (FDA) for donanemab, the company’s investigational antibody therapy for Alzheimer's disease (AD).</p>\n<p>This designation is granted to companies in a bid to accelerate the development and review of therapies meant to treat serious conditions when preliminary clinical results show that the relevant drug is ahead of already available therapies that have received full FDA approval.</p>\n<p>Donanemab is an investigational antibody treatment developed by Lilly’s that targets a modified form of beta-amyloid named N3pG. In its Phase 2 trial, the company studied the efficacy and safety of the drug in patients with early Alzheimer’s disease.</p>\n<p>Stifel analyst Paul Matteis says the designation has “multiple implications for the sector.” Shares of Biogen (NASDAQ: BIIB) are down over 5% on LLY news.</p>\n<p>“LLY's plans to file donanemab this morning for accelerated approval later this year is somewhat surprising to us from a timing perspective, not because of the efficacy data (good enough relative to Adu), but because we were unsure whether the FDA would be comfortable with the size of the safety dataset. This has multiple implications for BIIB (incrementally negative) and the abeta space,” the analyst said in a note.</p>\n<p>“On the <a href=\"https://laohu8.com/S/AONE\">one</a> hand, it increases competition for BIIB: LLY's actual clinical data are less confusing, and Biogen is mired in a string of bad press regarding pricing; competition could drive down the net price. Meanwhile, it also may impact the multiple that investors put in anti-amyloid agent revenues in general. Biogen has 9 years to complete its confirmatory trial; however, LLY's second donanemab study is ongoing and may readout considerably sooner, and may set up as a relevant catalyst, positive or negative, for the plight of both drugs.”</p>\n<p>Mizuho analyst Vamil Divan raised the price target on the Buy-rated LLY to $250.00 per share from $216.00 per share as “it is difficult to argue why donanemab would NOT be approved, given the speed and depth of plaque clearance donanemab demonstrated in TRAILBLAZER-ALZ and prior studies.”</p>\n<p>“We increase our probability of donanemab's regulatory approval to 90% (from 60%), assuming an accelerated approval will be based on amyloid plaque clearance, something donanemab has already consistently demonstrated. We also move up our donanemab launch to the start of 2023 (from 2024), but acknowledge this could even prove to still be a little conservative. However, we note that BIIB has guided to only “modest” revenues this year after its June 7 approval, so would assume fairly limited donanemab sales in 2022 even if Lilly gets an approval in the middle of the year. On the other hand, Lilly may be able to leverage some of what BIIB is doing now to secure coverage and access for anti-amyloid therapies, allowing for potentially more rapid market uptake. Lilly would also have the potential advantage of having confirmatory clinical data much sooner than BIIB, given their TRAILBLAZER-ALZ 2 trial is ongoing, with recruitment expected to be completed by year-end and full data expected by mid-2023,” Divan writes in a report on LLY.</p>\n<p>“We now estimate donanemab probability-adjusted sales of ~$11Bn in 2030, with room for further upside given the size of the Alzheimer's market. Our donanemab estimate changes drive our Lilly price target to $250 (from $217), with room for upside on a faster approval, a higher price (we currently assume $30K net per patient per year in the US and $15K in the EU and Japan), more rapid market uptake and/or higher peak sales. Our price target based on a 75%/25% blend of discounted cash flow (DCF) valuation at $259 and relative valuation at $222. Our DCF is based on cash flows forecasted through 2030, along with a 6.5% discount rate and a 0.5% rate of terminal growth. Our relative valuation is based on a 30.0x multiple of 2021 P/E using our estimate of Lilly’s 2021 EPS.”</p>\n<p>Lilly plans to apply for the biologics license (BLA) for donanemab under the expedited approval pathway later in 2021 based on data from Phase 2. The safety and efficacy of the drug are also being assessed in the ongoing Phase 3 study.</p>","source":"highlight_streetinsider","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Eli Lilly Surges After Getting Breakthrough Therapy Designation From FDA, Analyst Raises PT and Sees Approval Chance at 90%, Biogen Plunges</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEli Lilly Surges After Getting Breakthrough Therapy Designation From FDA, Analyst Raises PT and Sees Approval Chance at 90%, Biogen Plunges\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-25 07:55 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.streetinsider.com/dr/news.php?id=18600310><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Shares of Eli Lilly and Company (NYSE: LLY) are up over 9% in today’s trading session after the company obtained the Breakthrough Therapy designation by the U.S. Food and Drug Administration (FDA) for...</p>\n\n<a href=\"https://www.streetinsider.com/dr/news.php?id=18600310\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://www.streetinsider.com/dr/news.php?id=18600310","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2145042230","content_text":"Shares of Eli Lilly and Company (NYSE: LLY) are up over 9% in today’s trading session after the company obtained the Breakthrough Therapy designation by the U.S. Food and Drug Administration (FDA) for donanemab, the company’s investigational antibody therapy for Alzheimer's disease (AD).\nThis designation is granted to companies in a bid to accelerate the development and review of therapies meant to treat serious conditions when preliminary clinical results show that the relevant drug is ahead of already available therapies that have received full FDA approval.\nDonanemab is an investigational antibody treatment developed by Lilly’s that targets a modified form of beta-amyloid named N3pG. In its Phase 2 trial, the company studied the efficacy and safety of the drug in patients with early Alzheimer’s disease.\nStifel analyst Paul Matteis says the designation has “multiple implications for the sector.” Shares of Biogen (NASDAQ: BIIB) are down over 5% on LLY news.\n“LLY's plans to file donanemab this morning for accelerated approval later this year is somewhat surprising to us from a timing perspective, not because of the efficacy data (good enough relative to Adu), but because we were unsure whether the FDA would be comfortable with the size of the safety dataset. This has multiple implications for BIIB (incrementally negative) and the abeta space,” the analyst said in a note.\n“On the one hand, it increases competition for BIIB: LLY's actual clinical data are less confusing, and Biogen is mired in a string of bad press regarding pricing; competition could drive down the net price. Meanwhile, it also may impact the multiple that investors put in anti-amyloid agent revenues in general. Biogen has 9 years to complete its confirmatory trial; however, LLY's second donanemab study is ongoing and may readout considerably sooner, and may set up as a relevant catalyst, positive or negative, for the plight of both drugs.”\nMizuho analyst Vamil Divan raised the price target on the Buy-rated LLY to $250.00 per share from $216.00 per share as “it is difficult to argue why donanemab would NOT be approved, given the speed and depth of plaque clearance donanemab demonstrated in TRAILBLAZER-ALZ and prior studies.”\n“We increase our probability of donanemab's regulatory approval to 90% (from 60%), assuming an accelerated approval will be based on amyloid plaque clearance, something donanemab has already consistently demonstrated. We also move up our donanemab launch to the start of 2023 (from 2024), but acknowledge this could even prove to still be a little conservative. However, we note that BIIB has guided to only “modest” revenues this year after its June 7 approval, so would assume fairly limited donanemab sales in 2022 even if Lilly gets an approval in the middle of the year. On the other hand, Lilly may be able to leverage some of what BIIB is doing now to secure coverage and access for anti-amyloid therapies, allowing for potentially more rapid market uptake. Lilly would also have the potential advantage of having confirmatory clinical data much sooner than BIIB, given their TRAILBLAZER-ALZ 2 trial is ongoing, with recruitment expected to be completed by year-end and full data expected by mid-2023,” Divan writes in a report on LLY.\n“We now estimate donanemab probability-adjusted sales of ~$11Bn in 2030, with room for further upside given the size of the Alzheimer's market. Our donanemab estimate changes drive our Lilly price target to $250 (from $217), with room for upside on a faster approval, a higher price (we currently assume $30K net per patient per year in the US and $15K in the EU and Japan), more rapid market uptake and/or higher peak sales. Our price target based on a 75%/25% blend of discounted cash flow (DCF) valuation at $259 and relative valuation at $222. Our DCF is based on cash flows forecasted through 2030, along with a 6.5% discount rate and a 0.5% rate of terminal growth. Our relative valuation is based on a 30.0x multiple of 2021 P/E using our estimate of Lilly’s 2021 EPS.”\nLilly plans to apply for the biologics license (BLA) for donanemab under the expedited approval pathway later in 2021 based on data from Phase 2. The safety and efficacy of the drug are also being assessed in the ongoing Phase 3 study.","news_type":1,"symbols_score_info":{"BIIB":0.9,"LLY":0.9}},"isVote":1,"tweetType":1,"viewCount":408,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":126412277,"gmtCreate":1624581491999,"gmtModify":1633951026573,"author":{"id":"3575079452242155","authorId":"3575079452242155","name":"Joannnag","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3575079452242155","authorIdStr":"3575079452242155"},"themes":[],"htmlText":"Nice!","listText":"Nice!","text":"Nice!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/126412277","repostId":"2146023477","repostType":4,"isVote":1,"tweetType":1,"viewCount":622,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":126551576,"gmtCreate":1624579576995,"gmtModify":1633951085683,"author":{"id":"3575079452242155","authorId":"3575079452242155","name":"Joannnag","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3575079452242155","authorIdStr":"3575079452242155"},"themes":[],"htmlText":"When ipo?","listText":"When ipo?","text":"When ipo?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/126551576","repostId":"2146255080","repostType":4,"repost":{"id":"2146255080","kind":"highlight","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1624577871,"share":"https://ttm.financial/m/news/2146255080?lang=&edition=full","pubTime":"2021-06-25 07:37","market":"sh","language":"en","title":"Chinese ride-hailing giant DiDi targets over $60 bln valuation in NYSE debut","url":"https://stock-news.laohu8.com/highlight/detail?id=2146255080","media":"Reuters","summary":"June 24 (Reuters) - DiDi Global Inc , China's largest ride-hailing company, is aiming for a valuatio","content":"<p>June 24 (Reuters) - DiDi Global Inc , China's largest ride-hailing company, is aiming for a valuation of more than $60 billion in its New York Stock Exchange debut, setting it up for what is likely to be the biggest U.S. initial public offering (IPO) this year.</p>\n<p>It set a price range of between $13 and $14 per American Depositary Share (ADS) and said it would offer 288 million such shares in its IPO. At the upper end of the price range, DiDi expects to raise a little more than $4 billion.</p>\n<p>Four ADSs represent one Class A ordinary share, it said in a regulatory filing on Thursday that was registered under its formal name Xiaoju Kuaizhi Inc.</p>\n<p>The IPO will be the one of the biggest share sales by any Chinese company in the United States since Alibaba raised $25 billion in 2014.</p>\n<p>However, the terms of the offering suggest a conservative approach from DiDi, which had at one point been in talks to raise as much as $10 billion at a valuation of nearly $100 billion.&nbsp;</p>\n<p>The company is backed by Asia's largest technology investment firms including SoftBank Group Corp(9984.T), Alibaba Group Holdings(9988.HK)and Tencent Holdings(0700.HK).</p>\n<p>Before settling for a New York float, DiDi had considered Hong Kong as a potential listing venue for a multi-billion dollar IPO in 2021.</p>\n<p>Excluding China, DiDi, the world's largest mobility-technology platform, operates in 15 countries and has more than 493 million annual active users globally.</p>\n<p>It counts as its core business a mobile app used to hail taxis, privately owned cars, car-pool options and even buses in some cities.</p>\n<p>It became the top online ride-hailing business in China after market-share battles with Alibaba-backed Kuaidi and Silicon Valley-based Uber's China unit, both of which were merged with DiDi when investors sought profit from the money-losing businesses.</p>\n<p>In 2016, Uber Technologies Inc(UBER.N)sold its operation to DiDi for a 17.5% stake in the Chinese firm, which also made a $1 billion investment in Uber. The U.S. firm now owns 12.8% stake in DiDi, according to the IPO filings.</p>\n<p>In addition to ride-sharing, DiDi operates different businesses around mobility, including electric vehicle charging networks, fleet management, car making and autonomous driving.</p>\n<p>Goldman Sachs (Asia), Morgan Stanley and J.P. Morgan are the lead underwriters.</p>\n<p>DiDi added more than a dozen new ones on Thursday, including BofA Securities, Barclays, China Renaissance, Citigroup, HSBC and UBS Investment Bank.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Chinese ride-hailing giant DiDi targets over $60 bln valuation in NYSE debut</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nChinese ride-hailing giant DiDi targets over $60 bln valuation in NYSE debut\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-06-25 07:37</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>June 24 (Reuters) - DiDi Global Inc , China's largest ride-hailing company, is aiming for a valuation of more than $60 billion in its New York Stock Exchange debut, setting it up for what is likely to be the biggest U.S. initial public offering (IPO) this year.</p>\n<p>It set a price range of between $13 and $14 per American Depositary Share (ADS) and said it would offer 288 million such shares in its IPO. At the upper end of the price range, DiDi expects to raise a little more than $4 billion.</p>\n<p>Four ADSs represent one Class A ordinary share, it said in a regulatory filing on Thursday that was registered under its formal name Xiaoju Kuaizhi Inc.</p>\n<p>The IPO will be the one of the biggest share sales by any Chinese company in the United States since Alibaba raised $25 billion in 2014.</p>\n<p>However, the terms of the offering suggest a conservative approach from DiDi, which had at one point been in talks to raise as much as $10 billion at a valuation of nearly $100 billion.&nbsp;</p>\n<p>The company is backed by Asia's largest technology investment firms including SoftBank Group Corp(9984.T), Alibaba Group Holdings(9988.HK)and Tencent Holdings(0700.HK).</p>\n<p>Before settling for a New York float, DiDi had considered Hong Kong as a potential listing venue for a multi-billion dollar IPO in 2021.</p>\n<p>Excluding China, DiDi, the world's largest mobility-technology platform, operates in 15 countries and has more than 493 million annual active users globally.</p>\n<p>It counts as its core business a mobile app used to hail taxis, privately owned cars, car-pool options and even buses in some cities.</p>\n<p>It became the top online ride-hailing business in China after market-share battles with Alibaba-backed Kuaidi and Silicon Valley-based Uber's China unit, both of which were merged with DiDi when investors sought profit from the money-losing businesses.</p>\n<p>In 2016, Uber Technologies Inc(UBER.N)sold its operation to DiDi for a 17.5% stake in the Chinese firm, which also made a $1 billion investment in Uber. The U.S. firm now owns 12.8% stake in DiDi, according to the IPO filings.</p>\n<p>In addition to ride-sharing, DiDi operates different businesses around mobility, including electric vehicle charging networks, fleet management, car making and autonomous driving.</p>\n<p>Goldman Sachs (Asia), Morgan Stanley and J.P. Morgan are the lead underwriters.</p>\n<p>DiDi added more than a dozen new ones on Thursday, including BofA Securities, Barclays, China Renaissance, Citigroup, HSBC and UBS Investment Bank.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2146255080","content_text":"June 24 (Reuters) - DiDi Global Inc , China's largest ride-hailing company, is aiming for a valuation of more than $60 billion in its New York Stock Exchange debut, setting it up for what is likely to be the biggest U.S. initial public offering (IPO) this year.\nIt set a price range of between $13 and $14 per American Depositary Share (ADS) and said it would offer 288 million such shares in its IPO. At the upper end of the price range, DiDi expects to raise a little more than $4 billion.\nFour ADSs represent one Class A ordinary share, it said in a regulatory filing on Thursday that was registered under its formal name Xiaoju Kuaizhi Inc.\nThe IPO will be the one of the biggest share sales by any Chinese company in the United States since Alibaba raised $25 billion in 2014.\nHowever, the terms of the offering suggest a conservative approach from DiDi, which had at one point been in talks to raise as much as $10 billion at a valuation of nearly $100 billion. \nThe company is backed by Asia's largest technology investment firms including SoftBank Group Corp(9984.T), Alibaba Group Holdings(9988.HK)and Tencent Holdings(0700.HK).\nBefore settling for a New York float, DiDi had considered Hong Kong as a potential listing venue for a multi-billion dollar IPO in 2021.\nExcluding China, DiDi, the world's largest mobility-technology platform, operates in 15 countries and has more than 493 million annual active users globally.\nIt counts as its core business a mobile app used to hail taxis, privately owned cars, car-pool options and even buses in some cities.\nIt became the top online ride-hailing business in China after market-share battles with Alibaba-backed Kuaidi and Silicon Valley-based Uber's China unit, both of which were merged with DiDi when investors sought profit from the money-losing businesses.\nIn 2016, Uber Technologies Inc(UBER.N)sold its operation to DiDi for a 17.5% stake in the Chinese firm, which also made a $1 billion investment in Uber. The U.S. firm now owns 12.8% stake in DiDi, according to the IPO filings.\nIn addition to ride-sharing, DiDi operates different businesses around mobility, including electric vehicle charging networks, fleet management, car making and autonomous driving.\nGoldman Sachs (Asia), Morgan Stanley and J.P. Morgan are the lead underwriters.\nDiDi added more than a dozen new ones on Thursday, including BofA Securities, Barclays, China Renaissance, Citigroup, HSBC and UBS Investment Bank.","news_type":1,"symbols_score_info":{"DIDI":0.9,"UBER":0.9}},"isVote":1,"tweetType":1,"viewCount":739,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":126553559,"gmtCreate":1624579563571,"gmtModify":1633951086607,"author":{"id":"3575079452242155","authorId":"3575079452242155","name":"Joannnag","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3575079452242155","authorIdStr":"3575079452242155"},"themes":[],"htmlText":"Good news!","listText":"Good news!","text":"Good news!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/126553559","repostId":"2146202596","repostType":4,"isVote":1,"tweetType":1,"viewCount":377,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":129058605,"gmtCreate":1624346758207,"gmtModify":1634007453447,"author":{"id":"3575079452242155","authorId":"3575079452242155","name":"Joannnag","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3575079452242155","authorIdStr":"3575079452242155"},"themes":[],"htmlText":"Great","listText":"Great","text":"Great","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/129058605","repostId":"2145032477","repostType":4,"isVote":1,"tweetType":1,"viewCount":664,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":120183646,"gmtCreate":1624315011785,"gmtModify":1634008088554,"author":{"id":"3575079452242155","authorId":"3575079452242155","name":"Joannnag","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3575079452242155","authorIdStr":"3575079452242155"},"themes":[],"htmlText":"Hopefully soon!","listText":"Hopefully soon!","text":"Hopefully soon!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/120183646","repostId":"1127414335","repostType":4,"isVote":1,"tweetType":1,"viewCount":366,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":120189519,"gmtCreate":1624314974531,"gmtModify":1634008089246,"author":{"id":"3575079452242155","authorId":"3575079452242155","name":"Joannnag","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3575079452242155","authorIdStr":"3575079452242155"},"themes":[],"htmlText":"Really","listText":"Really","text":"Really","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/120189519","repostId":"2145084835","repostType":4,"repost":{"id":"2145084835","kind":"highlight","pubTimestamp":1624280460,"share":"https://ttm.financial/m/news/2145084835?lang=&edition=full","pubTime":"2021-06-21 21:01","market":"us","language":"en","title":"5 Ultra-Popular Stocks Wall Street Views as Overvalued","url":"https://stock-news.laohu8.com/highlight/detail?id=2145084835","media":"Motley Fool","summary":"If analysts are correct, these high-flying stocks will fizzle out over the next year.","content":"<p>Generally speaking, it pays to be bullish on Wall Street. Despite navigating its way through Black Monday in 1987, the dot-com bubble, the Great Recession, and more recently the coronavirus crash, the average annual total return for the benchmark <b>S&amp;P 500</b> since 1980, including dividends, is north of 11%.</p>\n<p>Not surprisingly, we see this optimism readily apparent in Wall Street's ratings on stocks. According to <b>FactSet</b>, more than half of all stocks carry a consensus buy rating, 38% have the equivalent of a hold rating, and just 7% are rated as sells. Yet, history shows that far more than 7% of stocks will eventually head lower.</p>\n<p>Based on Wall Street's consensus price targets, the following five ultra-popular stocks are all expected to lose value over the coming 12 months.</p>\n<p><img src=\"https://static.tigerbbs.com/b04ade705354c4825038c4dfcd0187d9\" tg-width=\"700\" tg-height=\"500\" referrerpolicy=\"no-referrer\"></p>\n<p>Image source: Getty Images.</p>\n<h3>Palantir Technologies: Implied downside of 12%</h3>\n<p>Since its direct listing in late September 2020, data-mining company <b>Palantir Technologies</b> (NYSE:PLTR) has been a favorite among growth and retail investors. But if Wall Street's <a href=\"https://laohu8.com/S/AONE\">one</a>-year consensus price target proves accurate, Palantir will head in reverse by up to 12%.</p>\n<p>The likeliest reason Wall Street is tempering expectations on Palantir is valuation. Specifically, Palantir ended June 17 with a market cap of nearly $48 billion, but is on track to bring in perhaps $1.5 billion in full-year sales in 2021. That's a multiple of about 32 times sales. Even if Palantir continues to grow its top-line at 30% annually, it could take years for this price-to-sales multiple to come down to anywhere close to the average for cloud stocks.</p>\n<p>Another possible concern is the growth potential for its government-focused Gotham platform. Big government contract wins in the U.S. have been primarily responsible for Palantir's exceptional growth rate. However, there remains an outside chance that President Joe Biden may curb funding to some of the federal agencies that employ Palantir's services.</p>\n<p>Over the long run, I'm optimistic and believe Palantir's platform is unlike anything else available. But tempering near-term expectations given its valuation premium may be warranted.</p>\n<p><img src=\"https://static.tigerbbs.com/a38605bee8e62f3e8aa414fa24278e7e\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\"></p>\n<p>Image source: Getty Images.</p>\n<h3>Moderna: Implied downside of 11%</h3>\n<p>Biotech stock <b>Moderna</b> (NASDAQ:MRNA) is arguably the biggest beneficiary of the coronavirus disease 2019 (COVID-19) pandemic. It's <a href=\"https://laohu8.com/S/AONE.U\">one</a> of only three drugmakers to currently have their COVID-19 vaccine approved on an emergency-use authorization (EUA) basis in the United States. But if Wall Street's consensus 12-month price target is correct, it's stock is also on its way to a double-digit decline.</p>\n<p>Why the lack of love from Wall Street? The answer looks to be analysts looking to the future. While Moderna's COVID-19 vaccine is a mainstay in the U.S., and it's likely to play a clear role in other markets, time might prove the company's enemy. Over time, new vaccines are expected to come onto the scene, which'll eat away at Moderna's potential pool of patients.</p>\n<p>The other worry is that no one is exactly certain how long COVID-19 vaccine immunity will last. If it's a year, Moderna is unlikely to be the only drugmaker supplying booster shots. Meanwhile, if it's longer than a year, it means reduced sales opportunities for the company.</p>\n<p>Based solely on Wall Street's earnings per share consensus in 2021 and 2022, Moderna appears reasonably priced. But with the company staring down a potentially significant haircut in revenue next year as new drugmakers enter the space, caution is advised.</p>\n<p><img src=\"https://static.tigerbbs.com/07841e6a8173146a0fbfddf95a0f1ccb\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\"></p>\n<p>Image source: Getty Images.</p>\n<h3>GameStop: Implied downside of 71%</h3>\n<p>This will probably come as a shock to no one, but Reddit favorite <b>GameStop</b> (NYSE:GME) is fully expected to fall flat on its face. Even though Wall Street's consensus price target for the company has quintupled in recent months, it <i>still</i> implies up to 71% downside over the next year.</p>\n<p>The biggest issue for GameStop is that its valuation has completely detached from its underlying fundamentals. While it's not uncommon for stocks to trade on emotion for short periods of time, operating performance is what always dictates the long-term movement in the share price of a stock. When it comes to operating performance, GameStop has been a dud.</p>\n<p>Although the company's first-quarter fiscal results highlighted a 25% net sales increase from the prior-year period, total sales for the company have been falling precipitously for years. That's because video game retailer GameStop recognized the shift to digital gaming too late, and it's now stuck with its massive portfolio of brick-and-mortar gaming stores. Even though e-commerce sales have been a bright spot for the company, slashing costs and closing stores remains its No. 1 priority.</p>\n<p>With sufficient cash, bankruptcy isn't a concern for GameStop. But without any true top-line growth and the company still losing money, it's an impossible sell at its current price tag.</p>\n<p><img src=\"https://static.tigerbbs.com/c7ff785aa0040a5565d474390f58b47a\" tg-width=\"700\" tg-height=\"457\" referrerpolicy=\"no-referrer\"></p>\n<p>Image source: Getty Images.</p>\n<h3>Ocugen: Implied downside of 18%</h3>\n<p>Volatile clinical-stage biotech stock <b>Ocugen</b> (NASDAQ:OCGN) may also be in for an unpleasant next 12 months. The company behind an experimental COVID-19 vaccine (Covaxin) and a trio of internally developed eye-blindness candidates is expected to shed 18% of its value, if Wall Street's consensus price target is correct.</p>\n<p>Arguably the biggest issue for Ocugen is the clinical update the company issued on June 10 concerning Covaxin. Even though partner Bharat Biotech led a large clinical study in India that yielded an overall efficacy of 78%, along with 100% efficacy in preventing severe forms of COVID-19, Ocugen announced on June 10 that it would forgo seeking an EUA in the U.S. and would instead file for a biologics license application. In other words, Ocugen's path to a quick emergency approval in the U.S. just flew out the window.</p>\n<p>What's more, the U.S. Food and Drug Administration's requested additional information and data on Covaxin. This is a fancy of saying that Ocugen will very likely have to run a clinical study in the U.S. prior to submitting Covaxin for approval. That means added costs and an even longer wait before Ocugen has a chance to penetrate the lucrative U.S. market.</p>\n<p>Though it's impossible to predict how long COVID-19 vaccine immunity will last, Ocugen's chances of being a significant player in the U.S. COVID-19 vaccine space are dwindling.</p>\n<p><img src=\"https://static.tigerbbs.com/91f6037829ea3fb0ae1cae0b95d8d11e\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\"></p>\n<p>Image source: Getty Images.</p>\n<h3>NVIDIA: Implied downside of 3%</h3>\n<p>Don't adjust your computer, laptop, or smartphone screens -- that really says <b>NVIDIA</b> (NASDAQ:NVDA). Following its incredible run higher (NVIDIA has doubled over the past year), graphics processing unit giant NVIDIA closed 3% above Wall Street's consensus price target, as of June 17.</p>\n<p>One reason for tempered expectations at this point has to be valuation. Even with NVIDIA crushing expectations and seeing strong PC gaming demand, sales growth is expected to slow from an estimated 49% in fiscal 2022 to a high single digit percentage in each of the next two fiscal years. In fact, the company closed at nearly 20 times projected sales for the current fiscal year. That's a bit optimistic given an expected sales growth slowdown.</p>\n<p>Perhaps the other reason Wall Street expects NVIDIA to go sideways is the company's cryptocurrency mining chip segment. While sales of crypto chips could hit $400 million in the current quarter, demand is entirely dependent on the hype surrounding digital currencies and the favorability of technical charts. Crypto is just as well known for its long bear markets as it is for the big gains it's delivered over the past decade. If another lull strikes, a fast-growing ancillary segment for NVIDA could easily become a drag.</p>\n<p>For what it's worth, I see no fundamental reasons to sell NVIDIA if you're already a long-term shareholder. But if you're on the outside looking in, I don't exactly see $746 as an attractive entry point, either.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>5 Ultra-Popular Stocks Wall Street Views as Overvalued</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n5 Ultra-Popular Stocks Wall Street Views as Overvalued\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-21 21:01 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/06/21/5-ultra-popular-stocks-wall-street-view-overvalued/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Generally speaking, it pays to be bullish on Wall Street. Despite navigating its way through Black Monday in 1987, the dot-com bubble, the Great Recession, and more recently the coronavirus crash, the...</p>\n\n<a href=\"https://www.fool.com/investing/2021/06/21/5-ultra-popular-stocks-wall-street-view-overvalued/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://www.fool.com/investing/2021/06/21/5-ultra-popular-stocks-wall-street-view-overvalued/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2145084835","content_text":"Generally speaking, it pays to be bullish on Wall Street. Despite navigating its way through Black Monday in 1987, the dot-com bubble, the Great Recession, and more recently the coronavirus crash, the average annual total return for the benchmark S&P 500 since 1980, including dividends, is north of 11%.\nNot surprisingly, we see this optimism readily apparent in Wall Street's ratings on stocks. According to FactSet, more than half of all stocks carry a consensus buy rating, 38% have the equivalent of a hold rating, and just 7% are rated as sells. Yet, history shows that far more than 7% of stocks will eventually head lower.\nBased on Wall Street's consensus price targets, the following five ultra-popular stocks are all expected to lose value over the coming 12 months.\n\nImage source: Getty Images.\nPalantir Technologies: Implied downside of 12%\nSince its direct listing in late September 2020, data-mining company Palantir Technologies (NYSE:PLTR) has been a favorite among growth and retail investors. But if Wall Street's one-year consensus price target proves accurate, Palantir will head in reverse by up to 12%.\nThe likeliest reason Wall Street is tempering expectations on Palantir is valuation. Specifically, Palantir ended June 17 with a market cap of nearly $48 billion, but is on track to bring in perhaps $1.5 billion in full-year sales in 2021. That's a multiple of about 32 times sales. Even if Palantir continues to grow its top-line at 30% annually, it could take years for this price-to-sales multiple to come down to anywhere close to the average for cloud stocks.\nAnother possible concern is the growth potential for its government-focused Gotham platform. Big government contract wins in the U.S. have been primarily responsible for Palantir's exceptional growth rate. However, there remains an outside chance that President Joe Biden may curb funding to some of the federal agencies that employ Palantir's services.\nOver the long run, I'm optimistic and believe Palantir's platform is unlike anything else available. But tempering near-term expectations given its valuation premium may be warranted.\n\nImage source: Getty Images.\nModerna: Implied downside of 11%\nBiotech stock Moderna (NASDAQ:MRNA) is arguably the biggest beneficiary of the coronavirus disease 2019 (COVID-19) pandemic. It's one of only three drugmakers to currently have their COVID-19 vaccine approved on an emergency-use authorization (EUA) basis in the United States. But if Wall Street's consensus 12-month price target is correct, it's stock is also on its way to a double-digit decline.\nWhy the lack of love from Wall Street? The answer looks to be analysts looking to the future. While Moderna's COVID-19 vaccine is a mainstay in the U.S., and it's likely to play a clear role in other markets, time might prove the company's enemy. Over time, new vaccines are expected to come onto the scene, which'll eat away at Moderna's potential pool of patients.\nThe other worry is that no one is exactly certain how long COVID-19 vaccine immunity will last. If it's a year, Moderna is unlikely to be the only drugmaker supplying booster shots. Meanwhile, if it's longer than a year, it means reduced sales opportunities for the company.\nBased solely on Wall Street's earnings per share consensus in 2021 and 2022, Moderna appears reasonably priced. But with the company staring down a potentially significant haircut in revenue next year as new drugmakers enter the space, caution is advised.\n\nImage source: Getty Images.\nGameStop: Implied downside of 71%\nThis will probably come as a shock to no one, but Reddit favorite GameStop (NYSE:GME) is fully expected to fall flat on its face. Even though Wall Street's consensus price target for the company has quintupled in recent months, it still implies up to 71% downside over the next year.\nThe biggest issue for GameStop is that its valuation has completely detached from its underlying fundamentals. While it's not uncommon for stocks to trade on emotion for short periods of time, operating performance is what always dictates the long-term movement in the share price of a stock. When it comes to operating performance, GameStop has been a dud.\nAlthough the company's first-quarter fiscal results highlighted a 25% net sales increase from the prior-year period, total sales for the company have been falling precipitously for years. That's because video game retailer GameStop recognized the shift to digital gaming too late, and it's now stuck with its massive portfolio of brick-and-mortar gaming stores. Even though e-commerce sales have been a bright spot for the company, slashing costs and closing stores remains its No. 1 priority.\nWith sufficient cash, bankruptcy isn't a concern for GameStop. But without any true top-line growth and the company still losing money, it's an impossible sell at its current price tag.\n\nImage source: Getty Images.\nOcugen: Implied downside of 18%\nVolatile clinical-stage biotech stock Ocugen (NASDAQ:OCGN) may also be in for an unpleasant next 12 months. The company behind an experimental COVID-19 vaccine (Covaxin) and a trio of internally developed eye-blindness candidates is expected to shed 18% of its value, if Wall Street's consensus price target is correct.\nArguably the biggest issue for Ocugen is the clinical update the company issued on June 10 concerning Covaxin. Even though partner Bharat Biotech led a large clinical study in India that yielded an overall efficacy of 78%, along with 100% efficacy in preventing severe forms of COVID-19, Ocugen announced on June 10 that it would forgo seeking an EUA in the U.S. and would instead file for a biologics license application. In other words, Ocugen's path to a quick emergency approval in the U.S. just flew out the window.\nWhat's more, the U.S. Food and Drug Administration's requested additional information and data on Covaxin. This is a fancy of saying that Ocugen will very likely have to run a clinical study in the U.S. prior to submitting Covaxin for approval. That means added costs and an even longer wait before Ocugen has a chance to penetrate the lucrative U.S. market.\nThough it's impossible to predict how long COVID-19 vaccine immunity will last, Ocugen's chances of being a significant player in the U.S. COVID-19 vaccine space are dwindling.\n\nImage source: Getty Images.\nNVIDIA: Implied downside of 3%\nDon't adjust your computer, laptop, or smartphone screens -- that really says NVIDIA (NASDAQ:NVDA). Following its incredible run higher (NVIDIA has doubled over the past year), graphics processing unit giant NVIDIA closed 3% above Wall Street's consensus price target, as of June 17.\nOne reason for tempered expectations at this point has to be valuation. Even with NVIDIA crushing expectations and seeing strong PC gaming demand, sales growth is expected to slow from an estimated 49% in fiscal 2022 to a high single digit percentage in each of the next two fiscal years. In fact, the company closed at nearly 20 times projected sales for the current fiscal year. That's a bit optimistic given an expected sales growth slowdown.\nPerhaps the other reason Wall Street expects NVIDIA to go sideways is the company's cryptocurrency mining chip segment. While sales of crypto chips could hit $400 million in the current quarter, demand is entirely dependent on the hype surrounding digital currencies and the favorability of technical charts. Crypto is just as well known for its long bear markets as it is for the big gains it's delivered over the past decade. If another lull strikes, a fast-growing ancillary segment for NVIDA could easily become a drag.\nFor what it's worth, I see no fundamental reasons to sell NVIDIA if you're already a long-term shareholder. But if you're on the outside looking in, I don't exactly see $746 as an attractive entry point, either.","news_type":1,"symbols_score_info":{"GME":0.9,"MRNA":0.9,"NVDA":0.9,"OCGN":0.9,"PLTR":0.9}},"isVote":1,"tweetType":1,"viewCount":521,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":164351852,"gmtCreate":1624173710776,"gmtModify":1634009787406,"author":{"id":"3575079452242155","authorId":"3575079452242155","name":"Joannnag","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3575079452242155","authorIdStr":"3575079452242155"},"themes":[],"htmlText":"Really?","listText":"Really?","text":"Really?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/164351852","repostId":"1126454279","repostType":4,"isVote":1,"tweetType":1,"viewCount":186,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":164383553,"gmtCreate":1624171759772,"gmtModify":1634009815325,"author":{"id":"3575079452242155","authorId":"3575079452242155","name":"Joannnag","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3575079452242155","authorIdStr":"3575079452242155"},"themes":[],"htmlText":"Great","listText":"Great","text":"Great","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/164383553","repostId":"1138062216","repostType":4,"isVote":1,"tweetType":1,"viewCount":411,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":164383660,"gmtCreate":1624171742750,"gmtModify":1634009815569,"author":{"id":"3575079452242155","authorId":"3575079452242155","name":"Joannnag","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3575079452242155","authorIdStr":"3575079452242155"},"themes":[],"htmlText":"Up","listText":"Up","text":"Up","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/164383660","repostId":"1138062216","repostType":4,"isVote":1,"tweetType":1,"viewCount":228,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"hots":[{"id":126412277,"gmtCreate":1624581491999,"gmtModify":1633951026573,"author":{"id":"3575079452242155","authorId":"3575079452242155","name":"Joannnag","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3575079452242155","authorIdStr":"3575079452242155"},"themes":[],"htmlText":"Nice!","listText":"Nice!","text":"Nice!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/126412277","repostId":"2146023477","repostType":4,"isVote":1,"tweetType":1,"viewCount":622,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":126551576,"gmtCreate":1624579576995,"gmtModify":1633951085683,"author":{"id":"3575079452242155","authorId":"3575079452242155","name":"Joannnag","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3575079452242155","authorIdStr":"3575079452242155"},"themes":[],"htmlText":"When ipo?","listText":"When ipo?","text":"When ipo?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/126551576","repostId":"2146255080","repostType":4,"repost":{"id":"2146255080","kind":"highlight","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1624577871,"share":"https://ttm.financial/m/news/2146255080?lang=&edition=full","pubTime":"2021-06-25 07:37","market":"sh","language":"en","title":"Chinese ride-hailing giant DiDi targets over $60 bln valuation in NYSE debut","url":"https://stock-news.laohu8.com/highlight/detail?id=2146255080","media":"Reuters","summary":"June 24 (Reuters) - DiDi Global Inc , China's largest ride-hailing company, is aiming for a valuatio","content":"<p>June 24 (Reuters) - DiDi Global Inc , China's largest ride-hailing company, is aiming for a valuation of more than $60 billion in its New York Stock Exchange debut, setting it up for what is likely to be the biggest U.S. initial public offering (IPO) this year.</p>\n<p>It set a price range of between $13 and $14 per American Depositary Share (ADS) and said it would offer 288 million such shares in its IPO. At the upper end of the price range, DiDi expects to raise a little more than $4 billion.</p>\n<p>Four ADSs represent one Class A ordinary share, it said in a regulatory filing on Thursday that was registered under its formal name Xiaoju Kuaizhi Inc.</p>\n<p>The IPO will be the one of the biggest share sales by any Chinese company in the United States since Alibaba raised $25 billion in 2014.</p>\n<p>However, the terms of the offering suggest a conservative approach from DiDi, which had at one point been in talks to raise as much as $10 billion at a valuation of nearly $100 billion.&nbsp;</p>\n<p>The company is backed by Asia's largest technology investment firms including SoftBank Group Corp(9984.T), Alibaba Group Holdings(9988.HK)and Tencent Holdings(0700.HK).</p>\n<p>Before settling for a New York float, DiDi had considered Hong Kong as a potential listing venue for a multi-billion dollar IPO in 2021.</p>\n<p>Excluding China, DiDi, the world's largest mobility-technology platform, operates in 15 countries and has more than 493 million annual active users globally.</p>\n<p>It counts as its core business a mobile app used to hail taxis, privately owned cars, car-pool options and even buses in some cities.</p>\n<p>It became the top online ride-hailing business in China after market-share battles with Alibaba-backed Kuaidi and Silicon Valley-based Uber's China unit, both of which were merged with DiDi when investors sought profit from the money-losing businesses.</p>\n<p>In 2016, Uber Technologies Inc(UBER.N)sold its operation to DiDi for a 17.5% stake in the Chinese firm, which also made a $1 billion investment in Uber. The U.S. firm now owns 12.8% stake in DiDi, according to the IPO filings.</p>\n<p>In addition to ride-sharing, DiDi operates different businesses around mobility, including electric vehicle charging networks, fleet management, car making and autonomous driving.</p>\n<p>Goldman Sachs (Asia), Morgan Stanley and J.P. Morgan are the lead underwriters.</p>\n<p>DiDi added more than a dozen new ones on Thursday, including BofA Securities, Barclays, China Renaissance, Citigroup, HSBC and UBS Investment Bank.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Chinese ride-hailing giant DiDi targets over $60 bln valuation in NYSE debut</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nChinese ride-hailing giant DiDi targets over $60 bln valuation in NYSE debut\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-06-25 07:37</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>June 24 (Reuters) - DiDi Global Inc , China's largest ride-hailing company, is aiming for a valuation of more than $60 billion in its New York Stock Exchange debut, setting it up for what is likely to be the biggest U.S. initial public offering (IPO) this year.</p>\n<p>It set a price range of between $13 and $14 per American Depositary Share (ADS) and said it would offer 288 million such shares in its IPO. At the upper end of the price range, DiDi expects to raise a little more than $4 billion.</p>\n<p>Four ADSs represent one Class A ordinary share, it said in a regulatory filing on Thursday that was registered under its formal name Xiaoju Kuaizhi Inc.</p>\n<p>The IPO will be the one of the biggest share sales by any Chinese company in the United States since Alibaba raised $25 billion in 2014.</p>\n<p>However, the terms of the offering suggest a conservative approach from DiDi, which had at one point been in talks to raise as much as $10 billion at a valuation of nearly $100 billion.&nbsp;</p>\n<p>The company is backed by Asia's largest technology investment firms including SoftBank Group Corp(9984.T), Alibaba Group Holdings(9988.HK)and Tencent Holdings(0700.HK).</p>\n<p>Before settling for a New York float, DiDi had considered Hong Kong as a potential listing venue for a multi-billion dollar IPO in 2021.</p>\n<p>Excluding China, DiDi, the world's largest mobility-technology platform, operates in 15 countries and has more than 493 million annual active users globally.</p>\n<p>It counts as its core business a mobile app used to hail taxis, privately owned cars, car-pool options and even buses in some cities.</p>\n<p>It became the top online ride-hailing business in China after market-share battles with Alibaba-backed Kuaidi and Silicon Valley-based Uber's China unit, both of which were merged with DiDi when investors sought profit from the money-losing businesses.</p>\n<p>In 2016, Uber Technologies Inc(UBER.N)sold its operation to DiDi for a 17.5% stake in the Chinese firm, which also made a $1 billion investment in Uber. The U.S. firm now owns 12.8% stake in DiDi, according to the IPO filings.</p>\n<p>In addition to ride-sharing, DiDi operates different businesses around mobility, including electric vehicle charging networks, fleet management, car making and autonomous driving.</p>\n<p>Goldman Sachs (Asia), Morgan Stanley and J.P. Morgan are the lead underwriters.</p>\n<p>DiDi added more than a dozen new ones on Thursday, including BofA Securities, Barclays, China Renaissance, Citigroup, HSBC and UBS Investment Bank.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2146255080","content_text":"June 24 (Reuters) - DiDi Global Inc , China's largest ride-hailing company, is aiming for a valuation of more than $60 billion in its New York Stock Exchange debut, setting it up for what is likely to be the biggest U.S. initial public offering (IPO) this year.\nIt set a price range of between $13 and $14 per American Depositary Share (ADS) and said it would offer 288 million such shares in its IPO. At the upper end of the price range, DiDi expects to raise a little more than $4 billion.\nFour ADSs represent one Class A ordinary share, it said in a regulatory filing on Thursday that was registered under its formal name Xiaoju Kuaizhi Inc.\nThe IPO will be the one of the biggest share sales by any Chinese company in the United States since Alibaba raised $25 billion in 2014.\nHowever, the terms of the offering suggest a conservative approach from DiDi, which had at one point been in talks to raise as much as $10 billion at a valuation of nearly $100 billion. \nThe company is backed by Asia's largest technology investment firms including SoftBank Group Corp(9984.T), Alibaba Group Holdings(9988.HK)and Tencent Holdings(0700.HK).\nBefore settling for a New York float, DiDi had considered Hong Kong as a potential listing venue for a multi-billion dollar IPO in 2021.\nExcluding China, DiDi, the world's largest mobility-technology platform, operates in 15 countries and has more than 493 million annual active users globally.\nIt counts as its core business a mobile app used to hail taxis, privately owned cars, car-pool options and even buses in some cities.\nIt became the top online ride-hailing business in China after market-share battles with Alibaba-backed Kuaidi and Silicon Valley-based Uber's China unit, both of which were merged with DiDi when investors sought profit from the money-losing businesses.\nIn 2016, Uber Technologies Inc(UBER.N)sold its operation to DiDi for a 17.5% stake in the Chinese firm, which also made a $1 billion investment in Uber. The U.S. firm now owns 12.8% stake in DiDi, according to the IPO filings.\nIn addition to ride-sharing, DiDi operates different businesses around mobility, including electric vehicle charging networks, fleet management, car making and autonomous driving.\nGoldman Sachs (Asia), Morgan Stanley and J.P. Morgan are the lead underwriters.\nDiDi added more than a dozen new ones on Thursday, including BofA Securities, Barclays, China Renaissance, Citigroup, HSBC and UBS Investment Bank.","news_type":1,"symbols_score_info":{"DIDI":0.9,"UBER":0.9}},"isVote":1,"tweetType":1,"viewCount":739,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":120189519,"gmtCreate":1624314974531,"gmtModify":1634008089246,"author":{"id":"3575079452242155","authorId":"3575079452242155","name":"Joannnag","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3575079452242155","authorIdStr":"3575079452242155"},"themes":[],"htmlText":"Really","listText":"Really","text":"Really","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/120189519","repostId":"2145084835","repostType":4,"repost":{"id":"2145084835","kind":"highlight","pubTimestamp":1624280460,"share":"https://ttm.financial/m/news/2145084835?lang=&edition=full","pubTime":"2021-06-21 21:01","market":"us","language":"en","title":"5 Ultra-Popular Stocks Wall Street Views as Overvalued","url":"https://stock-news.laohu8.com/highlight/detail?id=2145084835","media":"Motley Fool","summary":"If analysts are correct, these high-flying stocks will fizzle out over the next year.","content":"<p>Generally speaking, it pays to be bullish on Wall Street. Despite navigating its way through Black Monday in 1987, the dot-com bubble, the Great Recession, and more recently the coronavirus crash, the average annual total return for the benchmark <b>S&amp;P 500</b> since 1980, including dividends, is north of 11%.</p>\n<p>Not surprisingly, we see this optimism readily apparent in Wall Street's ratings on stocks. According to <b>FactSet</b>, more than half of all stocks carry a consensus buy rating, 38% have the equivalent of a hold rating, and just 7% are rated as sells. Yet, history shows that far more than 7% of stocks will eventually head lower.</p>\n<p>Based on Wall Street's consensus price targets, the following five ultra-popular stocks are all expected to lose value over the coming 12 months.</p>\n<p><img src=\"https://static.tigerbbs.com/b04ade705354c4825038c4dfcd0187d9\" tg-width=\"700\" tg-height=\"500\" referrerpolicy=\"no-referrer\"></p>\n<p>Image source: Getty Images.</p>\n<h3>Palantir Technologies: Implied downside of 12%</h3>\n<p>Since its direct listing in late September 2020, data-mining company <b>Palantir Technologies</b> (NYSE:PLTR) has been a favorite among growth and retail investors. But if Wall Street's <a href=\"https://laohu8.com/S/AONE\">one</a>-year consensus price target proves accurate, Palantir will head in reverse by up to 12%.</p>\n<p>The likeliest reason Wall Street is tempering expectations on Palantir is valuation. Specifically, Palantir ended June 17 with a market cap of nearly $48 billion, but is on track to bring in perhaps $1.5 billion in full-year sales in 2021. That's a multiple of about 32 times sales. Even if Palantir continues to grow its top-line at 30% annually, it could take years for this price-to-sales multiple to come down to anywhere close to the average for cloud stocks.</p>\n<p>Another possible concern is the growth potential for its government-focused Gotham platform. Big government contract wins in the U.S. have been primarily responsible for Palantir's exceptional growth rate. However, there remains an outside chance that President Joe Biden may curb funding to some of the federal agencies that employ Palantir's services.</p>\n<p>Over the long run, I'm optimistic and believe Palantir's platform is unlike anything else available. But tempering near-term expectations given its valuation premium may be warranted.</p>\n<p><img src=\"https://static.tigerbbs.com/a38605bee8e62f3e8aa414fa24278e7e\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\"></p>\n<p>Image source: Getty Images.</p>\n<h3>Moderna: Implied downside of 11%</h3>\n<p>Biotech stock <b>Moderna</b> (NASDAQ:MRNA) is arguably the biggest beneficiary of the coronavirus disease 2019 (COVID-19) pandemic. It's <a href=\"https://laohu8.com/S/AONE.U\">one</a> of only three drugmakers to currently have their COVID-19 vaccine approved on an emergency-use authorization (EUA) basis in the United States. But if Wall Street's consensus 12-month price target is correct, it's stock is also on its way to a double-digit decline.</p>\n<p>Why the lack of love from Wall Street? The answer looks to be analysts looking to the future. While Moderna's COVID-19 vaccine is a mainstay in the U.S., and it's likely to play a clear role in other markets, time might prove the company's enemy. Over time, new vaccines are expected to come onto the scene, which'll eat away at Moderna's potential pool of patients.</p>\n<p>The other worry is that no one is exactly certain how long COVID-19 vaccine immunity will last. If it's a year, Moderna is unlikely to be the only drugmaker supplying booster shots. Meanwhile, if it's longer than a year, it means reduced sales opportunities for the company.</p>\n<p>Based solely on Wall Street's earnings per share consensus in 2021 and 2022, Moderna appears reasonably priced. But with the company staring down a potentially significant haircut in revenue next year as new drugmakers enter the space, caution is advised.</p>\n<p><img src=\"https://static.tigerbbs.com/07841e6a8173146a0fbfddf95a0f1ccb\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\"></p>\n<p>Image source: Getty Images.</p>\n<h3>GameStop: Implied downside of 71%</h3>\n<p>This will probably come as a shock to no one, but Reddit favorite <b>GameStop</b> (NYSE:GME) is fully expected to fall flat on its face. Even though Wall Street's consensus price target for the company has quintupled in recent months, it <i>still</i> implies up to 71% downside over the next year.</p>\n<p>The biggest issue for GameStop is that its valuation has completely detached from its underlying fundamentals. While it's not uncommon for stocks to trade on emotion for short periods of time, operating performance is what always dictates the long-term movement in the share price of a stock. When it comes to operating performance, GameStop has been a dud.</p>\n<p>Although the company's first-quarter fiscal results highlighted a 25% net sales increase from the prior-year period, total sales for the company have been falling precipitously for years. That's because video game retailer GameStop recognized the shift to digital gaming too late, and it's now stuck with its massive portfolio of brick-and-mortar gaming stores. Even though e-commerce sales have been a bright spot for the company, slashing costs and closing stores remains its No. 1 priority.</p>\n<p>With sufficient cash, bankruptcy isn't a concern for GameStop. But without any true top-line growth and the company still losing money, it's an impossible sell at its current price tag.</p>\n<p><img src=\"https://static.tigerbbs.com/c7ff785aa0040a5565d474390f58b47a\" tg-width=\"700\" tg-height=\"457\" referrerpolicy=\"no-referrer\"></p>\n<p>Image source: Getty Images.</p>\n<h3>Ocugen: Implied downside of 18%</h3>\n<p>Volatile clinical-stage biotech stock <b>Ocugen</b> (NASDAQ:OCGN) may also be in for an unpleasant next 12 months. The company behind an experimental COVID-19 vaccine (Covaxin) and a trio of internally developed eye-blindness candidates is expected to shed 18% of its value, if Wall Street's consensus price target is correct.</p>\n<p>Arguably the biggest issue for Ocugen is the clinical update the company issued on June 10 concerning Covaxin. Even though partner Bharat Biotech led a large clinical study in India that yielded an overall efficacy of 78%, along with 100% efficacy in preventing severe forms of COVID-19, Ocugen announced on June 10 that it would forgo seeking an EUA in the U.S. and would instead file for a biologics license application. In other words, Ocugen's path to a quick emergency approval in the U.S. just flew out the window.</p>\n<p>What's more, the U.S. Food and Drug Administration's requested additional information and data on Covaxin. This is a fancy of saying that Ocugen will very likely have to run a clinical study in the U.S. prior to submitting Covaxin for approval. That means added costs and an even longer wait before Ocugen has a chance to penetrate the lucrative U.S. market.</p>\n<p>Though it's impossible to predict how long COVID-19 vaccine immunity will last, Ocugen's chances of being a significant player in the U.S. COVID-19 vaccine space are dwindling.</p>\n<p><img src=\"https://static.tigerbbs.com/91f6037829ea3fb0ae1cae0b95d8d11e\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\"></p>\n<p>Image source: Getty Images.</p>\n<h3>NVIDIA: Implied downside of 3%</h3>\n<p>Don't adjust your computer, laptop, or smartphone screens -- that really says <b>NVIDIA</b> (NASDAQ:NVDA). Following its incredible run higher (NVIDIA has doubled over the past year), graphics processing unit giant NVIDIA closed 3% above Wall Street's consensus price target, as of June 17.</p>\n<p>One reason for tempered expectations at this point has to be valuation. Even with NVIDIA crushing expectations and seeing strong PC gaming demand, sales growth is expected to slow from an estimated 49% in fiscal 2022 to a high single digit percentage in each of the next two fiscal years. In fact, the company closed at nearly 20 times projected sales for the current fiscal year. That's a bit optimistic given an expected sales growth slowdown.</p>\n<p>Perhaps the other reason Wall Street expects NVIDIA to go sideways is the company's cryptocurrency mining chip segment. While sales of crypto chips could hit $400 million in the current quarter, demand is entirely dependent on the hype surrounding digital currencies and the favorability of technical charts. Crypto is just as well known for its long bear markets as it is for the big gains it's delivered over the past decade. If another lull strikes, a fast-growing ancillary segment for NVIDA could easily become a drag.</p>\n<p>For what it's worth, I see no fundamental reasons to sell NVIDIA if you're already a long-term shareholder. But if you're on the outside looking in, I don't exactly see $746 as an attractive entry point, either.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>5 Ultra-Popular Stocks Wall Street Views as Overvalued</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n5 Ultra-Popular Stocks Wall Street Views as Overvalued\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-21 21:01 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/06/21/5-ultra-popular-stocks-wall-street-view-overvalued/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Generally speaking, it pays to be bullish on Wall Street. Despite navigating its way through Black Monday in 1987, the dot-com bubble, the Great Recession, and more recently the coronavirus crash, the...</p>\n\n<a href=\"https://www.fool.com/investing/2021/06/21/5-ultra-popular-stocks-wall-street-view-overvalued/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://www.fool.com/investing/2021/06/21/5-ultra-popular-stocks-wall-street-view-overvalued/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2145084835","content_text":"Generally speaking, it pays to be bullish on Wall Street. Despite navigating its way through Black Monday in 1987, the dot-com bubble, the Great Recession, and more recently the coronavirus crash, the average annual total return for the benchmark S&P 500 since 1980, including dividends, is north of 11%.\nNot surprisingly, we see this optimism readily apparent in Wall Street's ratings on stocks. According to FactSet, more than half of all stocks carry a consensus buy rating, 38% have the equivalent of a hold rating, and just 7% are rated as sells. Yet, history shows that far more than 7% of stocks will eventually head lower.\nBased on Wall Street's consensus price targets, the following five ultra-popular stocks are all expected to lose value over the coming 12 months.\n\nImage source: Getty Images.\nPalantir Technologies: Implied downside of 12%\nSince its direct listing in late September 2020, data-mining company Palantir Technologies (NYSE:PLTR) has been a favorite among growth and retail investors. But if Wall Street's one-year consensus price target proves accurate, Palantir will head in reverse by up to 12%.\nThe likeliest reason Wall Street is tempering expectations on Palantir is valuation. Specifically, Palantir ended June 17 with a market cap of nearly $48 billion, but is on track to bring in perhaps $1.5 billion in full-year sales in 2021. That's a multiple of about 32 times sales. Even if Palantir continues to grow its top-line at 30% annually, it could take years for this price-to-sales multiple to come down to anywhere close to the average for cloud stocks.\nAnother possible concern is the growth potential for its government-focused Gotham platform. Big government contract wins in the U.S. have been primarily responsible for Palantir's exceptional growth rate. However, there remains an outside chance that President Joe Biden may curb funding to some of the federal agencies that employ Palantir's services.\nOver the long run, I'm optimistic and believe Palantir's platform is unlike anything else available. But tempering near-term expectations given its valuation premium may be warranted.\n\nImage source: Getty Images.\nModerna: Implied downside of 11%\nBiotech stock Moderna (NASDAQ:MRNA) is arguably the biggest beneficiary of the coronavirus disease 2019 (COVID-19) pandemic. It's one of only three drugmakers to currently have their COVID-19 vaccine approved on an emergency-use authorization (EUA) basis in the United States. But if Wall Street's consensus 12-month price target is correct, it's stock is also on its way to a double-digit decline.\nWhy the lack of love from Wall Street? The answer looks to be analysts looking to the future. While Moderna's COVID-19 vaccine is a mainstay in the U.S., and it's likely to play a clear role in other markets, time might prove the company's enemy. Over time, new vaccines are expected to come onto the scene, which'll eat away at Moderna's potential pool of patients.\nThe other worry is that no one is exactly certain how long COVID-19 vaccine immunity will last. If it's a year, Moderna is unlikely to be the only drugmaker supplying booster shots. Meanwhile, if it's longer than a year, it means reduced sales opportunities for the company.\nBased solely on Wall Street's earnings per share consensus in 2021 and 2022, Moderna appears reasonably priced. But with the company staring down a potentially significant haircut in revenue next year as new drugmakers enter the space, caution is advised.\n\nImage source: Getty Images.\nGameStop: Implied downside of 71%\nThis will probably come as a shock to no one, but Reddit favorite GameStop (NYSE:GME) is fully expected to fall flat on its face. Even though Wall Street's consensus price target for the company has quintupled in recent months, it still implies up to 71% downside over the next year.\nThe biggest issue for GameStop is that its valuation has completely detached from its underlying fundamentals. While it's not uncommon for stocks to trade on emotion for short periods of time, operating performance is what always dictates the long-term movement in the share price of a stock. When it comes to operating performance, GameStop has been a dud.\nAlthough the company's first-quarter fiscal results highlighted a 25% net sales increase from the prior-year period, total sales for the company have been falling precipitously for years. That's because video game retailer GameStop recognized the shift to digital gaming too late, and it's now stuck with its massive portfolio of brick-and-mortar gaming stores. Even though e-commerce sales have been a bright spot for the company, slashing costs and closing stores remains its No. 1 priority.\nWith sufficient cash, bankruptcy isn't a concern for GameStop. But without any true top-line growth and the company still losing money, it's an impossible sell at its current price tag.\n\nImage source: Getty Images.\nOcugen: Implied downside of 18%\nVolatile clinical-stage biotech stock Ocugen (NASDAQ:OCGN) may also be in for an unpleasant next 12 months. The company behind an experimental COVID-19 vaccine (Covaxin) and a trio of internally developed eye-blindness candidates is expected to shed 18% of its value, if Wall Street's consensus price target is correct.\nArguably the biggest issue for Ocugen is the clinical update the company issued on June 10 concerning Covaxin. Even though partner Bharat Biotech led a large clinical study in India that yielded an overall efficacy of 78%, along with 100% efficacy in preventing severe forms of COVID-19, Ocugen announced on June 10 that it would forgo seeking an EUA in the U.S. and would instead file for a biologics license application. In other words, Ocugen's path to a quick emergency approval in the U.S. just flew out the window.\nWhat's more, the U.S. Food and Drug Administration's requested additional information and data on Covaxin. This is a fancy of saying that Ocugen will very likely have to run a clinical study in the U.S. prior to submitting Covaxin for approval. That means added costs and an even longer wait before Ocugen has a chance to penetrate the lucrative U.S. market.\nThough it's impossible to predict how long COVID-19 vaccine immunity will last, Ocugen's chances of being a significant player in the U.S. COVID-19 vaccine space are dwindling.\n\nImage source: Getty Images.\nNVIDIA: Implied downside of 3%\nDon't adjust your computer, laptop, or smartphone screens -- that really says NVIDIA (NASDAQ:NVDA). Following its incredible run higher (NVIDIA has doubled over the past year), graphics processing unit giant NVIDIA closed 3% above Wall Street's consensus price target, as of June 17.\nOne reason for tempered expectations at this point has to be valuation. Even with NVIDIA crushing expectations and seeing strong PC gaming demand, sales growth is expected to slow from an estimated 49% in fiscal 2022 to a high single digit percentage in each of the next two fiscal years. In fact, the company closed at nearly 20 times projected sales for the current fiscal year. That's a bit optimistic given an expected sales growth slowdown.\nPerhaps the other reason Wall Street expects NVIDIA to go sideways is the company's cryptocurrency mining chip segment. While sales of crypto chips could hit $400 million in the current quarter, demand is entirely dependent on the hype surrounding digital currencies and the favorability of technical charts. Crypto is just as well known for its long bear markets as it is for the big gains it's delivered over the past decade. If another lull strikes, a fast-growing ancillary segment for NVIDA could easily become a drag.\nFor what it's worth, I see no fundamental reasons to sell NVIDIA if you're already a long-term shareholder. But if you're on the outside looking in, I don't exactly see $746 as an attractive entry point, either.","news_type":1,"symbols_score_info":{"GME":0.9,"MRNA":0.9,"NVDA":0.9,"OCGN":0.9,"PLTR":0.9}},"isVote":1,"tweetType":1,"viewCount":521,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":164351852,"gmtCreate":1624173710776,"gmtModify":1634009787406,"author":{"id":"3575079452242155","authorId":"3575079452242155","name":"Joannnag","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3575079452242155","authorIdStr":"3575079452242155"},"themes":[],"htmlText":"Really?","listText":"Really?","text":"Really?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/164351852","repostId":"1126454279","repostType":4,"isVote":1,"tweetType":1,"viewCount":186,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":164383553,"gmtCreate":1624171759772,"gmtModify":1634009815325,"author":{"id":"3575079452242155","authorId":"3575079452242155","name":"Joannnag","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3575079452242155","authorIdStr":"3575079452242155"},"themes":[],"htmlText":"Great","listText":"Great","text":"Great","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/164383553","repostId":"1138062216","repostType":4,"isVote":1,"tweetType":1,"viewCount":411,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":129058605,"gmtCreate":1624346758207,"gmtModify":1634007453447,"author":{"id":"3575079452242155","authorId":"3575079452242155","name":"Joannnag","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3575079452242155","authorIdStr":"3575079452242155"},"themes":[],"htmlText":"Great","listText":"Great","text":"Great","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/129058605","repostId":"2145032477","repostType":4,"isVote":1,"tweetType":1,"viewCount":664,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":164383660,"gmtCreate":1624171742750,"gmtModify":1634009815569,"author":{"id":"3575079452242155","authorId":"3575079452242155","name":"Joannnag","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3575079452242155","authorIdStr":"3575079452242155"},"themes":[],"htmlText":"Up","listText":"Up","text":"Up","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/164383660","repostId":"1138062216","repostType":4,"isVote":1,"tweetType":1,"viewCount":228,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":126553559,"gmtCreate":1624579563571,"gmtModify":1633951086607,"author":{"id":"3575079452242155","authorId":"3575079452242155","name":"Joannnag","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3575079452242155","authorIdStr":"3575079452242155"},"themes":[],"htmlText":"Good news!","listText":"Good news!","text":"Good news!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/126553559","repostId":"2146202596","repostType":4,"isVote":1,"tweetType":1,"viewCount":377,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":125453057,"gmtCreate":1624687778979,"gmtModify":1633949543908,"author":{"id":"3575079452242155","authorId":"3575079452242155","name":"Joannnag","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3575079452242155","authorIdStr":"3575079452242155"},"themes":[],"htmlText":"It takes time","listText":"It takes time","text":"It takes time","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/125453057","repostId":"1164137597","repostType":4,"isVote":1,"tweetType":1,"viewCount":515,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":126415165,"gmtCreate":1624581521157,"gmtModify":1633951025984,"author":{"id":"3575079452242155","authorId":"3575079452242155","name":"Joannnag","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3575079452242155","authorIdStr":"3575079452242155"},"themes":[],"htmlText":"Wow","listText":"Wow","text":"Wow","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/126415165","repostId":"2145042230","repostType":4,"repost":{"id":"2145042230","kind":"news","pubTimestamp":1624578900,"share":"https://ttm.financial/m/news/2145042230?lang=&edition=full","pubTime":"2021-06-25 07:55","market":"us","language":"en","title":"Eli Lilly Surges After Getting Breakthrough Therapy Designation From FDA, Analyst Raises PT and Sees Approval Chance at 90%, Biogen Plunges","url":"https://stock-news.laohu8.com/highlight/detail?id=2145042230","media":"StreetInsider","summary":"Shares of Eli Lilly and Company (NYSE: LLY) are up over 9% in today’s trading session after the comp","content":"<p>Shares of Eli Lilly and Company (NYSE: LLY) are up over 9% in today’s trading session after the company obtained the Breakthrough Therapy designation by the U.S. Food and Drug Administration (FDA) for donanemab, the company’s investigational antibody therapy for Alzheimer's disease (AD).</p>\n<p>This designation is granted to companies in a bid to accelerate the development and review of therapies meant to treat serious conditions when preliminary clinical results show that the relevant drug is ahead of already available therapies that have received full FDA approval.</p>\n<p>Donanemab is an investigational antibody treatment developed by Lilly’s that targets a modified form of beta-amyloid named N3pG. In its Phase 2 trial, the company studied the efficacy and safety of the drug in patients with early Alzheimer’s disease.</p>\n<p>Stifel analyst Paul Matteis says the designation has “multiple implications for the sector.” Shares of Biogen (NASDAQ: BIIB) are down over 5% on LLY news.</p>\n<p>“LLY's plans to file donanemab this morning for accelerated approval later this year is somewhat surprising to us from a timing perspective, not because of the efficacy data (good enough relative to Adu), but because we were unsure whether the FDA would be comfortable with the size of the safety dataset. This has multiple implications for BIIB (incrementally negative) and the abeta space,” the analyst said in a note.</p>\n<p>“On the <a href=\"https://laohu8.com/S/AONE\">one</a> hand, it increases competition for BIIB: LLY's actual clinical data are less confusing, and Biogen is mired in a string of bad press regarding pricing; competition could drive down the net price. Meanwhile, it also may impact the multiple that investors put in anti-amyloid agent revenues in general. Biogen has 9 years to complete its confirmatory trial; however, LLY's second donanemab study is ongoing and may readout considerably sooner, and may set up as a relevant catalyst, positive or negative, for the plight of both drugs.”</p>\n<p>Mizuho analyst Vamil Divan raised the price target on the Buy-rated LLY to $250.00 per share from $216.00 per share as “it is difficult to argue why donanemab would NOT be approved, given the speed and depth of plaque clearance donanemab demonstrated in TRAILBLAZER-ALZ and prior studies.”</p>\n<p>“We increase our probability of donanemab's regulatory approval to 90% (from 60%), assuming an accelerated approval will be based on amyloid plaque clearance, something donanemab has already consistently demonstrated. We also move up our donanemab launch to the start of 2023 (from 2024), but acknowledge this could even prove to still be a little conservative. However, we note that BIIB has guided to only “modest” revenues this year after its June 7 approval, so would assume fairly limited donanemab sales in 2022 even if Lilly gets an approval in the middle of the year. On the other hand, Lilly may be able to leverage some of what BIIB is doing now to secure coverage and access for anti-amyloid therapies, allowing for potentially more rapid market uptake. Lilly would also have the potential advantage of having confirmatory clinical data much sooner than BIIB, given their TRAILBLAZER-ALZ 2 trial is ongoing, with recruitment expected to be completed by year-end and full data expected by mid-2023,” Divan writes in a report on LLY.</p>\n<p>“We now estimate donanemab probability-adjusted sales of ~$11Bn in 2030, with room for further upside given the size of the Alzheimer's market. Our donanemab estimate changes drive our Lilly price target to $250 (from $217), with room for upside on a faster approval, a higher price (we currently assume $30K net per patient per year in the US and $15K in the EU and Japan), more rapid market uptake and/or higher peak sales. Our price target based on a 75%/25% blend of discounted cash flow (DCF) valuation at $259 and relative valuation at $222. Our DCF is based on cash flows forecasted through 2030, along with a 6.5% discount rate and a 0.5% rate of terminal growth. Our relative valuation is based on a 30.0x multiple of 2021 P/E using our estimate of Lilly’s 2021 EPS.”</p>\n<p>Lilly plans to apply for the biologics license (BLA) for donanemab under the expedited approval pathway later in 2021 based on data from Phase 2. The safety and efficacy of the drug are also being assessed in the ongoing Phase 3 study.</p>","source":"highlight_streetinsider","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Eli Lilly Surges After Getting Breakthrough Therapy Designation From FDA, Analyst Raises PT and Sees Approval Chance at 90%, Biogen Plunges</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEli Lilly Surges After Getting Breakthrough Therapy Designation From FDA, Analyst Raises PT and Sees Approval Chance at 90%, Biogen Plunges\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-25 07:55 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.streetinsider.com/dr/news.php?id=18600310><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Shares of Eli Lilly and Company (NYSE: LLY) are up over 9% in today’s trading session after the company obtained the Breakthrough Therapy designation by the U.S. Food and Drug Administration (FDA) for...</p>\n\n<a href=\"https://www.streetinsider.com/dr/news.php?id=18600310\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://www.streetinsider.com/dr/news.php?id=18600310","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2145042230","content_text":"Shares of Eli Lilly and Company (NYSE: LLY) are up over 9% in today’s trading session after the company obtained the Breakthrough Therapy designation by the U.S. Food and Drug Administration (FDA) for donanemab, the company’s investigational antibody therapy for Alzheimer's disease (AD).\nThis designation is granted to companies in a bid to accelerate the development and review of therapies meant to treat serious conditions when preliminary clinical results show that the relevant drug is ahead of already available therapies that have received full FDA approval.\nDonanemab is an investigational antibody treatment developed by Lilly’s that targets a modified form of beta-amyloid named N3pG. In its Phase 2 trial, the company studied the efficacy and safety of the drug in patients with early Alzheimer’s disease.\nStifel analyst Paul Matteis says the designation has “multiple implications for the sector.” Shares of Biogen (NASDAQ: BIIB) are down over 5% on LLY news.\n“LLY's plans to file donanemab this morning for accelerated approval later this year is somewhat surprising to us from a timing perspective, not because of the efficacy data (good enough relative to Adu), but because we were unsure whether the FDA would be comfortable with the size of the safety dataset. This has multiple implications for BIIB (incrementally negative) and the abeta space,” the analyst said in a note.\n“On the one hand, it increases competition for BIIB: LLY's actual clinical data are less confusing, and Biogen is mired in a string of bad press regarding pricing; competition could drive down the net price. Meanwhile, it also may impact the multiple that investors put in anti-amyloid agent revenues in general. Biogen has 9 years to complete its confirmatory trial; however, LLY's second donanemab study is ongoing and may readout considerably sooner, and may set up as a relevant catalyst, positive or negative, for the plight of both drugs.”\nMizuho analyst Vamil Divan raised the price target on the Buy-rated LLY to $250.00 per share from $216.00 per share as “it is difficult to argue why donanemab would NOT be approved, given the speed and depth of plaque clearance donanemab demonstrated in TRAILBLAZER-ALZ and prior studies.”\n“We increase our probability of donanemab's regulatory approval to 90% (from 60%), assuming an accelerated approval will be based on amyloid plaque clearance, something donanemab has already consistently demonstrated. We also move up our donanemab launch to the start of 2023 (from 2024), but acknowledge this could even prove to still be a little conservative. However, we note that BIIB has guided to only “modest” revenues this year after its June 7 approval, so would assume fairly limited donanemab sales in 2022 even if Lilly gets an approval in the middle of the year. On the other hand, Lilly may be able to leverage some of what BIIB is doing now to secure coverage and access for anti-amyloid therapies, allowing for potentially more rapid market uptake. Lilly would also have the potential advantage of having confirmatory clinical data much sooner than BIIB, given their TRAILBLAZER-ALZ 2 trial is ongoing, with recruitment expected to be completed by year-end and full data expected by mid-2023,” Divan writes in a report on LLY.\n“We now estimate donanemab probability-adjusted sales of ~$11Bn in 2030, with room for further upside given the size of the Alzheimer's market. Our donanemab estimate changes drive our Lilly price target to $250 (from $217), with room for upside on a faster approval, a higher price (we currently assume $30K net per patient per year in the US and $15K in the EU and Japan), more rapid market uptake and/or higher peak sales. Our price target based on a 75%/25% blend of discounted cash flow (DCF) valuation at $259 and relative valuation at $222. Our DCF is based on cash flows forecasted through 2030, along with a 6.5% discount rate and a 0.5% rate of terminal growth. Our relative valuation is based on a 30.0x multiple of 2021 P/E using our estimate of Lilly’s 2021 EPS.”\nLilly plans to apply for the biologics license (BLA) for donanemab under the expedited approval pathway later in 2021 based on data from Phase 2. The safety and efficacy of the drug are also being assessed in the ongoing Phase 3 study.","news_type":1,"symbols_score_info":{"BIIB":0.9,"LLY":0.9}},"isVote":1,"tweetType":1,"viewCount":408,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":120183646,"gmtCreate":1624315011785,"gmtModify":1634008088554,"author":{"id":"3575079452242155","authorId":"3575079452242155","name":"Joannnag","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3575079452242155","authorIdStr":"3575079452242155"},"themes":[],"htmlText":"Hopefully soon!","listText":"Hopefully soon!","text":"Hopefully soon!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/120183646","repostId":"1127414335","repostType":4,"isVote":1,"tweetType":1,"viewCount":366,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":125459754,"gmtCreate":1624687778978,"gmtModify":1633949544029,"author":{"id":"3575079452242155","authorId":"3575079452242155","name":"Joannnag","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3575079452242155","authorIdStr":"3575079452242155"},"themes":[],"htmlText":"It takes time","listText":"It takes time","text":"It takes time","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/125459754","repostId":"1164137597","repostType":4,"isVote":1,"tweetType":1,"viewCount":731,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":126417020,"gmtCreate":1624581560460,"gmtModify":1633951024257,"author":{"id":"3575079452242155","authorId":"3575079452242155","name":"Joannnag","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3575079452242155","authorIdStr":"3575079452242155"},"themes":[],"htmlText":"Oh no","listText":"Oh no","text":"Oh no","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/126417020","repostId":"1162964404","repostType":4,"isVote":1,"tweetType":1,"viewCount":572,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"lives":[]}